Comparative Pharmacology
Head-to-head clinical analysis: DRIXORAL versus EVALOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIXORAL versus EVALOSE.
DRIXORAL vs EVALOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
None Documented
None Documented
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine/Decongestant
Antihistamine